l carnitine and l glutamine L-Carnitine Co Enzyme Q10 L Carnitine

Add them here

3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy

Cardiovasc Toxicol 26 , 90 (2026)

DFO reduced chronic inflammation and symptoms of autoimmune diseases in animal studies (Figure 11A), resulting in amplified transcription of genes promoting erythropoiesis, glycolysis, and angiogenesis (Woo et al., 2006)

In further pharmacological experiments, LUT@PPS-PEG nano-composites were effectively taken up by SK-MEL-28 cells and significantly inhibited their proliferation and migration

starting immediately after burn and continuing until 24 hours before sacrifice Result:Improved all parameters related to burn wound healing (including reducing edema, inflammatory cell infiltration and necrosis, increasing the number of capillaries, reticulin and collagen fiber formation, preserving hair follicle count, enhancing wound re-epithelization rate, skin breaking strength and relative elongation, and decreasing water content in burned skin)